|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
in00000098150 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
110623s2010 nyua ob 001 0 eng |
| 005 |
20240626183903.1 |
| 010 |
|
|
|a 2020685863
|
| 019 |
|
|
|a 834603828
|a 923663526
|a 961567277
|a 962706178
|a 988413068
|a 992078116
|a 1037943029
|a 1038655284
|a 1045498585
|a 1055373088
|a 1066439045
|a 1081218319
|a 1153527275
|a 1181910281
|a 1259265509
|
| 020 |
|
|
|a 9781616684433
|q ebook
|
| 020 |
|
|
|a 1616684437
|
| 020 |
|
|
|z 9781616683214
|
| 020 |
|
|
|z 161668321X
|
| 029 |
1 |
|
|a AU@
|b 000069242245
|
| 029 |
1 |
|
|a AU@
|b 000053299555
|
| 029 |
1 |
|
|a DEBBG
|b BV043961434
|
| 029 |
1 |
|
|a DEBBG
|b BV044088808
|
| 029 |
1 |
|
|a DEBSZ
|b 481300341
|
| 029 |
1 |
|
|a NZ1
|b 15347071
|
| 035 |
|
|
|a (OCoLC)994499908
|z (OCoLC)834603828
|z (OCoLC)923663526
|z (OCoLC)961567277
|z (OCoLC)962706178
|z (OCoLC)988413068
|z (OCoLC)992078116
|z (OCoLC)1037943029
|z (OCoLC)1038655284
|z (OCoLC)1045498585
|z (OCoLC)1055373088
|z (OCoLC)1066439045
|z (OCoLC)1081218319
|z (OCoLC)1153527275
|z (OCoLC)1181910281
|z (OCoLC)1259265509
|
| 035 |
|
|
|a (OCoLC)ocn994499908
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|c DLC
|d XFH
|d OCLCO
|d OCLCF
|d OCLCQ
|d YDXCP
|d N$T
|d E7B
|d EBLCP
|d AZK
|d AGLDB
|d ICA
|d MOR
|d PIFAG
|d MERUC
|d ZCU
|d U3W
|d D6H
|d STF
|d WRM
|d VTS
|d COCUF
|d NRAMU
|d ICG
|d VT2
|d AU@
|d WYU
|d DKC
|d M8D
|d UX1
|d UKCRE
|d AJS
|d OCLCO
|d OCLCL
|d TMA
|d OCLCQ
|
| 050 |
0 |
0 |
|a RE320
|
| 060 |
0 |
0 |
|a 2011 A-625
|
| 060 |
1 |
0 |
|a WW 212
|
| 072 |
|
7 |
|a HEA
|x 037000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 063000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 617.773
|q OCoLC
|2 23/eng/20230216
|
| 245 |
0 |
0 |
|a Conjunctivitis :
|b symptoms, treatment, and prevention /
|c Anna R. Sallinger, editor.
|
| 264 |
|
1 |
|a New York :
|b Nova Biomedical Books,
|c [2010]
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Eye and vision research developments
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a CONJUNCTIVITIS: SYMPTOMS, TREATMENT AND PREVENTION ; CONTENTS ; PREFACE ; ALLERGIC DISORDERS OF THE CONJUNCTIVA ; ABSTRACT ; 1. INTRODUCTION ; 2. IMMUNOLOGY RELEVANT TO ALLERGIC EYE DISEASE ; 2.1. Introduction ; 2.2. Lymphocyte Activation ; 2.3. Immune Hypersensitivity Reaction in Allergic Eye Diseases ; 2.3.1. Antibody-Mediated Hypersensitivity in Allergic Eye Diseases ; 2.3.1.1. IgG-Mediated Hypersensitivity Immune Reactions ; 2.3.1.2. IgE-Mediated Hypersensitivity Immune Reactions ; 2.3.2. T-Lymphocite-Mediated Hypersensitivity in Allergic Eye Diseases.
|
| 505 |
8 |
|
|a 3. CELLS AND MEDIATORS IN ALLERGIC EYE DISEASE 3.1. Antigen ; 3.2. Antibodies ; 3.3. B Lymphocytes ; 3.4. Antigen Presenting Cells ; 3.5. Dendritic Cells ; 3.6. Major histocomapibility complex (MHC) ; 3.7. Tryptase ; 3.8. Histamine ; 3.9. Langerhans Cells (LC) ; 3.10. Mast Cells ; 3.11. Prostaglandins ; 3.12. Leukotrienes ; 3.13. Adhesion Molecules ; 3.14. Neutrophils ; 3.15. Complement ; 3.16. Matrix Metalloproteinases (MMP) ; 3.17. Growth Factors ; 3.18. Eosinophils ; 3.19. Epithelial Cells ; 3.20. Fibroblast ; 3.21. T-Lymphocytes.
|
| 505 |
8 |
|
|a 3.22. Co-Stimulatory Molecules and Receptors 3.24. Chemokines ; 4. PHARMACOLOGIC THERAPY OF ALLERGIC EYE DISEASE ; 4.1. Vasoconstrictors ; 4.2. Antihistamines ; 4.3. Mast Cell Stabilizers ; 4.4. Multimodal or Dual Acting Agents ; 4.5. Nonsteroidal Anti-Inflammatory Drugs (NSAID) ; 4.6. Steroids ; 4.7. Anti-Metabolites ; 4.8. Immunomodulators ; 5. SPECIFIC ALLERGIC EYE DISEASES ; 5.1. Allergic conjunctivitis ; 5.2. Vernal Keratoconjunctivitis ; 5.3. Giant Papillary Conjunctivitis ; 5.4. Atopic Keratoconjunctivitis ; 5.5. Contact Ocular Allergy ; CONCLUSION.
|
| 505 |
8 |
|
|a ACKNOWLEDGMENT REFERENCES ; NOVEL DRUG DELIVERY APPROACHES IN DRY EYE SYNDROME THERAPY ; ABSTRACT ; ABBREVIATIONS ; 1. INTRODUCTION ; 2. LACHRYMAL FUNCTIONAL UNIT AND DRY EYE SYNDROME ; 2.1. Causes of the Dry Eye ; 2.2. Signs and Symptoms of the Dry Eye ; 3. THERAPEUTIC APPROACHES OF THE DRY EYE SYNDROME ; 3.1. Current Therapeutic Strategies ; 3.1.1. Tear Substitution: Artificial Tear Substitutes and Lubricants ; 3.1.2. Tear Preservation ; 3.1.2.1. Occlusion of the Tear Drainage System ; 3.1.2.2. Other Methods of Tear Preservation ; 3.1.3. Pharmacological Stimulation of Natural Tears.
|
| 505 |
8 |
|
|a 3.1.4. Treatment of the Underlying Causes of Dry Eye Disease 3.1.4.1. Cyclosporine A ; 3.1.4.2. Topical Corticosteroids ; 3.1.4.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs) ; 3.1.4.4. Systemic Tetracyclines ; 3.1.4.5. Sexual Hormones ; 3.1.4.6. Topical Vitamin A ; 3.1.4.7. Topical Autologous Serum ; 3.1.4.8. Omega-6; 3.1.4.9. Botulinum Toxin A ; 3.1.4.10. Acupuncture ; 3.1.4.11. Antiviral Agents ; 3.2. Novel Therapeutic Strategies ; 3.2.1. Polymeric Nanoparticles ; 3.2.1.1. Natural Polymers ; 3.2.1.2. Polymeric Coating of Various Carrier Systems ; 3.2.2. Solid Lipid Nanoparticles.
|
| 546 |
|
|
|a English.
|
| 588 |
|
|
|a Description based on print version record.
|
| 590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
| 650 |
|
0 |
|a Conjunctivitis
|x Diagnosis.
|
| 650 |
|
0 |
|a Conjunctivitis
|x Prevention.
|
| 650 |
|
0 |
|a Conjunctivitis
|x Treatment.
|
| 650 |
|
0 |
|a Conjunctiva
|x Diseases.
|
| 650 |
|
0 |
|a Eye
|x Diseases.
|
| 650 |
|
0 |
|a Diseases.
|
| 650 |
|
0 |
|a Conjunctivitis.
|
| 650 |
|
2 |
|a Conjunctival Diseases
|
| 650 |
|
2 |
|a Eye Diseases
|
| 650 |
|
2 |
|a Disease
|
| 650 |
|
2 |
|a Conjunctivitis
|
| 650 |
|
7 |
|a illness.
|2 aat
|
| 650 |
|
7 |
|a disease.
|2 aat
|
| 700 |
1 |
|
|a Sallinger, Anna R.
|
| 758 |
|
|
|i has work:
|a Conjunctivitis (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCGm8vw6b3QyMPv3tBcDYvb
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|t Conjunctivitis
|d New York : Nova Biomedical Books, [2010]
|z 9781616683214
|w (DLC) 2011414786
|
| 830 |
|
0 |
|a Eye and vision research developments series.
|
| 852 |
|
|
|b E-Collections
|h ProQuest
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/mcphs/detail.action?docID=3020407
|z Full text (MCPHS users only)
|t 0
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL3020407
|
| 938 |
|
|
|a ebrary
|b EBRY
|n ebr10676697
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 540304
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 10373197
|
| 947 |
|
|
|a FLO
|x pq-ebc-base
|
| 999 |
f |
f |
|s 1f36d7fa-21ea-45ca-bc24-e411ec8f6fc4
|i 299e37fe-1144-4b07-8d26-6647e48e2c84
|t 0
|
| 952 |
f |
f |
|a Massachusetts College of Pharmacy and Health Sciences
|b Online
|c Online
|d E-Collections
|t 0
|e ProQuest
|h Other scheme
|
| 856 |
4 |
0 |
|t 0
|u https://ebookcentral.proquest.com/lib/mcphs/detail.action?docID=3020407
|y Full text (MCPHS users only)
|
